CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this...
Saved in:
Published in | Biomolecules (Basel, Switzerland) Vol. 10; no. 4; p. 497 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
25.03.2020
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. |
---|---|
AbstractList | Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls ( = 28) and in cases with prion disease ( = 84), AD ( = 38), and frontotemporal dementia (FTD) ( = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt−Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls ( n = 28) and in cases with prion disease ( n = 84), AD ( n = 38), and frontotemporal dementia (FTD) ( n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation. |
Audience | Academic |
Author | Capellari, Sabina Oeckl, Patrick Halbgebauer, Steffen Steinacker, Petra Baiardi, Simone Abu-Rumeileh, Samir Otto, Markus Parchi, Piero |
AuthorAffiliation | 3 IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy 1 Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40138 Bologna, Italy; samir.aburumeileh@gmail.com (S.A.-R.); simone.baiardi6@unibo.it (S.B.); sabina.capellari@unibo.it (S.C.) 4 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy 2 Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany; patrick.oeckl@uni-ulm.de (P.O.); steffen.halbgebauer@uni-ulm.de (S.H.); petra.steinacker@uni-ulm.de (P.S.) |
AuthorAffiliation_xml | – name: 1 Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40138 Bologna, Italy; samir.aburumeileh@gmail.com (S.A.-R.); simone.baiardi6@unibo.it (S.B.); sabina.capellari@unibo.it (S.C.) – name: 4 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy – name: 2 Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany; patrick.oeckl@uni-ulm.de (P.O.); steffen.halbgebauer@uni-ulm.de (S.H.); petra.steinacker@uni-ulm.de (P.S.) – name: 3 IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy |
Author_xml | – sequence: 1 givenname: Samir orcidid: 0000-0003-0631-8506 surname: Abu-Rumeileh fullname: Abu-Rumeileh, Samir – sequence: 2 givenname: Patrick orcidid: 0000-0002-7652-7023 surname: Oeckl fullname: Oeckl, Patrick – sequence: 3 givenname: Simone surname: Baiardi fullname: Baiardi, Simone – sequence: 4 givenname: Steffen surname: Halbgebauer fullname: Halbgebauer, Steffen – sequence: 5 givenname: Petra surname: Steinacker fullname: Steinacker, Petra – sequence: 6 givenname: Sabina surname: Capellari fullname: Capellari, Sabina – sequence: 7 givenname: Markus orcidid: 0000-0003-4273-4267 surname: Otto fullname: Otto, Markus – sequence: 8 givenname: Piero orcidid: 0000-0002-9444-9524 surname: Parchi fullname: Parchi, Piero |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32218217$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1rFDEYgAep2Fp78ywBLz24mo-ZSeYiLFvXFlYUa8FbSDLv7KbMJNskU6gn7_4C_56_xGy3LVsxBBLyPu-TNx_Piz3nHRTFS4LfMtbgd9r6gWBc4rLhT4oDSomYUM6-7-3M94ujGC9xbiJ3yp4V-2wTpIQfFL9m53N0oe3VaJN1aAHX0Ec0DYBO7XIFAeXFaf9jBXaA8Ofn74hObAQVAaWVcpvoPHiXfIJh7YPq0QkM4JJVSLkWfYWuB5MyC-iTz9OxVwGdjzrdrGGT_CVY7-6VL4qnneojHN2Nh8XF_MO32elk8fnj2Wy6mJiSizRpGRVdZbRiqqS1qUsBmJimgXwJHRaqrDQVqqKaNkwziltatTXgWogWuADCDouzrbf16lKugx1UuJFeWXm74MNSqpCs6UEqQeq21g0mhJcdF1pDV5eM60q1BOomu95vXetRD9CafPZ8C4-kjyPOruTSX0tOaV0TngXHd4Lgr0aISQ42Guh75cCPUVImSoo5oyyjr7foUuXSrOt8NpoNLqc1IxUvxa3w1W5FD6Xcv3kG3mwBE3yMAboHhGC5-VVy91dlnP6DG5tUyu-Wd7f9_5P-Akjs0Q4 |
CitedBy_id | crossref_primary_10_1016_j_nsa_2023_102438 crossref_primary_10_3389_fnins_2021_648743 crossref_primary_10_1016_j_neurobiolaging_2020_11_015 crossref_primary_10_1002_alz_13863 crossref_primary_10_3390_ijms23042051 crossref_primary_10_3390_cells9112476 crossref_primary_10_1080_17460794_2025_2480963 crossref_primary_10_1002_dad2_12402 crossref_primary_10_3390_medicina58040473 crossref_primary_10_1038_s41380_025_02939_9 crossref_primary_10_3390_neurolint16050079 |
Cites_doi | 10.1602/neurorx.1.2.213 10.1212/WNL.0b013e31821103e6 10.1007/s00415-006-0472-9 10.1111/nan.12461 10.1186/s13195-017-0331-1 10.1016/B978-0-444-63945-5.00009-X 10.1038/s41593-018-0238-6 10.1189/jlb.0510316 10.1002/mds.27872 10.1007/s12035-018-1421-1 10.1111/bpa.12695 10.1002/pmic.200900246 10.1038/s41598-017-10922-w 10.1016/0006-8993(91)91692-T 10.3233/JAD-180409 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W 10.1093/jb/mvq044 10.1016/0006-8993(94)91757-4 10.1002/mds.26987 10.1007/s00401-017-1683-0 10.1136/jnnp-2017-315942 10.1093/brain/awh249 10.1001/jamaneurol.2019.1071 10.1007/s00401-012-1002-8 10.1186/s13195-019-0533-9 10.1002/acn3.50980 10.1021/pr5006058 10.1016/S1474-4422(14)70090-0 10.1002/ana.20639 10.1093/brain/awr179 10.1212/WNL.0b013e31827f0fd1 10.1080/21678421.2016.1267768 10.1007/s00702-014-1304-1 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2020 MDPI AG 2020 by the authors. 2020 |
Copyright_xml | – notice: COPYRIGHT 2020 MDPI AG – notice: 2020 by the authors. 2020 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3390/biom10040497 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2218-273X |
ExternalDocumentID | oai_doaj_org_article_a816d6b901174f78bbef6437b5ad1e69 PMC7226617 A631574817 32218217 10_3390_biom10040497 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Italy |
GeographicLocations_xml | – name: Italy |
GrantInformation_xml | – fundername: EU Joint Programme - Neurodegenerative Disease Research (JPND) networks grantid: PreFrontAls, Genfi-Prox (01ED1512) – fundername: Ministero della Salute grantid: Ricerca Corrente – fundername: German Federal Ministry of Education and Research grantid: FTLDc 01GI1007A |
GroupedDBID | 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION EBD ESX FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IAO IHR KQ8 LK8 M1P M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RPM UKHRP CGR CUY CVF ECM EIF NPM 7X8 PJZUB PPXIY PQGLB 5PM PUEGO |
ID | FETCH-LOGICAL-c478t-d328f5cba3a426c648e01c99e049f08a45b28a52b293b320d25d6e0688de78e13 |
IEDL.DBID | M48 |
ISSN | 2218-273X |
IngestDate | Wed Aug 27 01:27:14 EDT 2025 Thu Aug 21 18:19:02 EDT 2025 Tue Aug 05 09:38:45 EDT 2025 Tue Jun 17 21:20:41 EDT 2025 Thu Apr 03 07:06:43 EDT 2025 Tue Jul 01 00:43:12 EDT 2025 Thu Apr 24 22:59:39 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | human prion disease chitinase-3-like protein 1 Alzheimer’s disease biomarkers frontotemporal dementia mass spectrometry neurofilament ligh chain Creutzfeldt–Jakob disease ubiquitin |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c478t-d328f5cba3a426c648e01c99e049f08a45b28a52b293b320d25d6e0688de78e13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
ORCID | 0000-0003-0631-8506 0000-0002-9444-9524 0000-0002-7652-7023 0000-0003-4273-4267 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/biom10040497 |
PMID | 32218217 |
PQID | 2384207323 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a816d6b901174f78bbef6437b5ad1e69 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7226617 proquest_miscellaneous_2384207323 gale_infotracmisc_A631574817 pubmed_primary_32218217 crossref_primary_10_3390_biom10040497 crossref_citationtrail_10_3390_biom10040497 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20200325 |
PublicationDateYYYYMMDD | 2020-03-25 |
PublicationDate_xml | – month: 3 year: 2020 text: 20200325 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Biomolecules (Basel, Switzerland) |
PublicationTitleAlternate | Biomolecules |
PublicationYear | 2020 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Morimoto (ref_29) 1996; 148 Parchi (ref_17) 2012; 124 Oeckl (ref_4) 2014; 13 Strong (ref_22) 2017; 18 Green (ref_18) 2007; 254 ref_14 Alafuzoff (ref_30) 2015; 122 Franceschini (ref_35) 2018; 44 Lattanzio (ref_27) 2017; 133 Blennow (ref_2) 2004; 1 ref_32 Kudo (ref_9) 1994; 639 Parchi (ref_16) 1999; 46 Franceschini (ref_28) 2017; 7 Corrado (ref_36) 2019; 56 Majetschak (ref_10) 2011; 89 Hillis (ref_21) 2011; 76 Pocchiari (ref_31) 2004; 127 Steinacker (ref_3) 2010; 10 Dubois (ref_19) 2014; 13 Kimura (ref_7) 2010; 147 Rascovsky (ref_20) 2011; 134 Wang (ref_8) 1991; 566 Armstrong (ref_23) 2013; 80 Capellari (ref_33) 2018; 10 Jucker (ref_1) 2018; 21 Baiardi (ref_34) 2017; 88 Respondek (ref_26) 2020; 35 Baiardi (ref_12) 2019; 29 Respondek (ref_24) 2017; 32 Steinacker (ref_13) 2019; 12 Brinkmalm (ref_6) 2019; 11 Mometto (ref_25) 2018; 66 Hansson (ref_5) 2017; 11 Iqbal (ref_11) 2005; 58 Zerr (ref_15) 2018; 153 |
References_xml | – volume: 1 start-page: 213 year: 2004 ident: ref_2 article-title: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease publication-title: NeuroRx doi: 10.1602/neurorx.1.2.213 – volume: 76 start-page: 1006 year: 2011 ident: ref_21 article-title: Classification of primary progressive aphasia and its variants publication-title: Neurology doi: 10.1212/WNL.0b013e31821103e6 – volume: 254 start-page: 901 year: 2007 ident: ref_18 article-title: Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis publication-title: J. Neurol. doi: 10.1007/s00415-006-0472-9 – volume: 44 start-page: 574 year: 2018 ident: ref_35 article-title: Regional pattern of microgliosis in sporadic Creutzfeldt-Jakob disease in relation to phenotypic variants and disease progression publication-title: Neuropathol. Appl. Neurobiol. doi: 10.1111/nan.12461 – volume: 10 start-page: 3 year: 2018 ident: ref_33 article-title: The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias publication-title: Alzheimers Res Ther. doi: 10.1186/s13195-017-0331-1 – volume: 153 start-page: 155 year: 2018 ident: ref_15 article-title: Sporadic Creutzfeldt-Jakob disease publication-title: Handbook of Clinical Neurology doi: 10.1016/B978-0-444-63945-5.00009-X – volume: 21 start-page: 1341 year: 2018 ident: ref_1 article-title: Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases publication-title: Nat Neurosci. doi: 10.1038/s41593-018-0238-6 – volume: 89 start-page: 205 year: 2011 ident: ref_10 article-title: Extracellular ubiquitin: Immune modulator and endogenous opponent of damage-associated molecular pattern molecules publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.0510316 – volume: 35 start-page: 171 year: 2020 ident: ref_26 article-title: Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies publication-title: Mov Disord. doi: 10.1002/mds.27872 – volume: 56 start-page: 5009 year: 2019 ident: ref_36 article-title: Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease publication-title: Mol Neurobiol. doi: 10.1007/s12035-018-1421-1 – volume: 29 start-page: 278 year: 2019 ident: ref_12 article-title: Recent advances in the histo-molecular pathology of human prion disease publication-title: Brain Pathol. doi: 10.1111/bpa.12695 – volume: 10 start-page: 81 year: 2010 ident: ref_3 article-title: Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease publication-title: Proteomics doi: 10.1002/pmic.200900246 – volume: 7 start-page: 10655 year: 2017 ident: ref_28 article-title: High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions publication-title: Sci. Rep. doi: 10.1038/s41598-017-10922-w – volume: 566 start-page: 146 year: 1991 ident: ref_8 article-title: Brain ubiquitin is markedly elevated in Alzheimer disease publication-title: Brain Res. doi: 10.1016/0006-8993(91)91692-T – volume: 66 start-page: 551 year: 2018 ident: ref_25 article-title: Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-180409 – volume: 46 start-page: 224 year: 1999 ident: ref_16 article-title: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects publication-title: Ann. Neurol. doi: 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W – volume: 147 start-page: 793 year: 2010 ident: ref_7 article-title: Regulatory mechanisms involved in the control of ubiquitin homeostasis publication-title: J. Biochem. doi: 10.1093/jb/mvq044 – volume: 639 start-page: 1 year: 1994 ident: ref_9 article-title: Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels publication-title: Brain Res. doi: 10.1016/0006-8993(94)91757-4 – volume: 32 start-page: 853 year: 2017 ident: ref_24 article-title: Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria publication-title: Mov. Disord. doi: 10.1002/mds.26987 – volume: 11 start-page: 11 year: 2017 ident: ref_5 article-title: Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders publication-title: Proteomics Clin Appl. – volume: 148 start-page: 249 year: 1996 ident: ref_29 article-title: Transient ischemia depletes free ubiquitin in the gerbil hippocampal CA1 neurons publication-title: Am. J. Pathol. – volume: 133 start-page: 559 year: 2017 ident: ref_27 article-title: Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: Diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels publication-title: Acta Neuropathol. doi: 10.1007/s00401-017-1683-0 – volume: 88 start-page: 764 year: 2017 ident: ref_34 article-title: Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type) publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp-2017-315942 – volume: 12 start-page: 2 year: 2019 ident: ref_13 article-title: CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia publication-title: Alzheimers Res Ther. – volume: 127 start-page: 2348 year: 2004 ident: ref_31 article-title: Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies publication-title: Brain doi: 10.1093/brain/awh249 – ident: ref_32 doi: 10.1001/jamaneurol.2019.1071 – volume: 124 start-page: 517 year: 2012 ident: ref_17 article-title: Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA publication-title: Acta Neuropathol. doi: 10.1007/s00401-012-1002-8 – volume: 11 start-page: 82 year: 2019 ident: ref_6 article-title: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease publication-title: Alzheimers Res Ther. doi: 10.1186/s13195-019-0533-9 – ident: ref_14 doi: 10.1002/acn3.50980 – volume: 13 start-page: 4518 year: 2014 ident: ref_4 article-title: Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer’s disease and frontotemporal lobar degeneration publication-title: J. Proteome Res. doi: 10.1021/pr5006058 – volume: 13 start-page: 614 year: 2014 ident: ref_19 article-title: Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(14)70090-0 – volume: 58 start-page: 748 year: 2005 ident: ref_11 article-title: Subgroups of Alzheimer’s disease based on cerebrospinal fluid molecular markers publication-title: Ann Neurol. doi: 10.1002/ana.20639 – volume: 134 start-page: 2456 year: 2011 ident: ref_20 article-title: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia publication-title: Brain doi: 10.1093/brain/awr179 – volume: 80 start-page: 496 year: 2013 ident: ref_23 article-title: Criteria for the diagnosis of corticobasal degeneration publication-title: Neurology doi: 10.1212/WNL.0b013e31827f0fd1 – volume: 18 start-page: 153 year: 2017 ident: ref_22 article-title: Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria publication-title: Amyotroph. Lateral Scler. Frontotemporal. Degener. doi: 10.1080/21678421.2016.1267768 – volume: 122 start-page: 957 year: 2015 ident: ref_30 article-title: Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: An inter-laboratory study by the BrainNet Europe consortium publication-title: J. Neural. Transm. doi: 10.1007/s00702-014-1304-1 |
SSID | ssj0000800823 |
Score | 2.2134955 |
Snippet | Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 497 |
SubjectTerms | Aged Alzheimer Disease - cerebrospinal fluid Alzheimer's disease Analysis Atomic properties Biological markers biomarkers Biomarkers - cerebrospinal fluid Brain - metabolism Brain - pathology Case-Control Studies Cerebrospinal fluid proteins chitinase-3-like protein 1 Comparative analysis Creutzfeldt-Jakob Syndrome - cerebrospinal fluid creutzfeldt–jakob disease Female Frontotemporal dementia Frontotemporal Dementia - cerebrospinal fluid human prion disease Humans Male mass spectrometry Measurement Middle Aged neurofilament ligh chain Prion diseases Prion Diseases - cerebrospinal fluid Prion Diseases - pathology Ubiquitin Ubiquitin - cerebrospinal fluid Ubiquitin - metabolism |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT70gaHkslMpIwAVFXTtx7ByXllWFKELASr1FfkzUoG0K-ziUE3d-AX-vv6QzcXaVCCEuXGM7cTJjzzeT8TeMvQjWI-gXWZKh_UAHRTg6rGwRyIEzvvIhkj2ffchPZ9m7c3XeK_VFOWGRHjh-uCNrRB5yRyckdVZp4xxU9LPJKRsE5O3RPbR5PWfqa4eDjExjpnuKfv0RnWYndjRExHpgg1qq_j835J5FGmZL9szP9B672-FGPonzvc_uQLPH9icN-syX1_wVbzM52xD5Pvt1_HnKZ67-vq5XdcPfU17QEocCj1kdHC9O5j8uoL6Exc3P30t-En_TcIqjU-u0pTXoaKvm_KSNIdaW2ybwT1BRqB_7Aj_bFNfluAFRNJcGf1ygrDe3fMBm07dfjk-TruhC4jNtVklIpamUdza1aLx9nhkYC18UgB-uGhubKYeyVNIhTnCpHAepQg5UuiaANiDSh2ynuWrgMePKyKBsYTTkeG8hbU5MQUXhhfZWChix1xsxlL5jJKfCGPMSPRMSWtkX2oi93Pb-Fpk4_tLvDUl024f4s9sLqFVlp1Xlv7RqxA5IH0pa5Tglj2vOl5M8FUqjZuMznm_0pKQmSlRr4Gq9LBEBZRK3TZmO2KOoN9uZ4N6J3hyN1gONGkx12NLUFy3lt5YEpPST__FuT9mupKDBOE2kOmA7q8UaniGyWrnDdhHdAg_zItE priority: 102 providerName: Directory of Open Access Journals |
Title | CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32218217 https://www.proquest.com/docview/2384207323 https://pubmed.ncbi.nlm.nih.gov/PMC7226617 https://doaj.org/article/a816d6b901174f78bbef6437b5ad1e69 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB71IaFeEFCgCyUyEnBBgdj7sPeAUPqIKkSqqhApt5Xt9dJF6YZuEoly4s4v4O_xS5jZR0hUuHBd27vWesbzzXj8DcCzVFsE_TzoBmg_0EHhhi4rawRyziib2bQmex6eRiej4N04HG9AW220-YGzv7p2VE9qVE5efb26fosK_4Y8TnTZX9NFdSI-Q7ArN2EbbZIkFR02QP9zg4uU8OvM9xuDduAWyjUi7aps2R_zVLH439yrV4zVeiLlimUa3IHbDaRk_VoG7sKGK-7Bbr9Ad_rymr1gVZJnFT3fhR-HHwZsZPKrRT7PC_aeUoZmONSxOuGD4cP-5NuFyy9d-ev7zxk7qk9wGIXYqXVQMR40jFYTdlSFF3PNdJGyc5fRKQD2dWzY1t1luDdRoJcGn5UoBu0r78NocPzx8KTb1GPo2kCqeTf1hcpCa7Sv0a7bKFCux20cO_yHWU_pIDS4zKEwCCGML3qpCNPIUVWb1EnluP8Atopp4faAhUqkoY6VdBG-mwsdEYlQHFsurRbcefCyXYbENmTlVDNjkqDTQuuXrK6fB8-Xvb_UJB3_6HdAK7rsQ9Ta1YNp-SlpNDXRikdpZOhKrgwyqYxxGZ1umlCn3EWxB_skDwmJJE7JojrapB_5PJQo9PiNp62cJNREOWyFmy5mCYKjQOCOKnwPHtZys5xJK34eyDWJWpvqekuRX1Rs4FIQxpKP_nvkY9gRFETo-V0R7sPWvFy4J4i05qYDm3IsO7B9cHx6dt6p4hWdSrF-A37tLYQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CSF+Ubiquitin+Levels+Are+Higher+in+Alzheimer%E2%80%99s+Disease+than+in+Frontotemporal+Dementia+and+Reflect+the+Molecular+Subtype+in+Prion+Disease&rft.jtitle=Biomolecules+%28Basel%2C+Switzerland%29&rft.au=Abu-Rumeileh%2C+Samir&rft.au=Oeckl%2C+Patrick&rft.au=Baiardi%2C+Simone&rft.au=Halbgebauer%2C+Steffen&rft.date=2020-03-25&rft.pub=MDPI&rft.eissn=2218-273X&rft.volume=10&rft.issue=4&rft_id=info:doi/10.3390%2Fbiom10040497&rft_id=info%3Apmid%2F32218217&rft.externalDocID=PMC7226617 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-273X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-273X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-273X&client=summon |